Registered title, quoted from ClinicalTrials.gov
Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG
An open trial on coronary heart disease, registered on ClinicalTrials.gov. Led by Second Hospital of Jilin University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06981390, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 2
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (2 points)Hide the checklist
18 years to 80 years; sex: all
Registered eligibility fields
Pregnant or breastfeeding women, and those who have given birth within the past 90 days.
Exclusion criterion 16
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06981390, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients 18-80 of age.
- Patients undergo planned CABG for the first time with ≥1 SVGs
- Patients with written informed consent.
Exclusion Criteria:
- Patients undergoing concomitant valve surgery (excluding aortic bioprosthesis), aortic surgery, or rhythm surgery during the same session.
- Patients undergoing emergency CABG.
- Patients with single-vessel coronary artery disease.
- Patients with cardiogenic shock or hemodynamic instability.
- Patients with sick sinus syndrome, second- or third-degree atrioventricular block.
- Patients with contraindications for coronary computed tomography angiography (CCTA) or coronary angiography, including contrast media allergy.
- Patients requiring antiplatelet therapy other than aspirin or ticagrelor (e.g., clopidogrel, prasugrel) and unable to discontinue such medication after CABG, based on physician or investigator judgment.
- Patients on oral anticoagulants before CABG who must continue anticoagulation therapy postoperatively.
- Patients with contraindications for ticagrelor or aspirin, including:
9.1Bleeding diathesis within the past 3 months. 9.2Severe gastrointestinal bleeding within the past year. 9.3Peptic ulcer (even without bleeding) within the past 3 years. 9.4History of intracranial hemorrhage, aspirin allergy, or severe aspirin-induced gastrointestinal reaction.
- Patients with a drug-eluting stent (DES) in a coronary or cerebral artery within 6 months before CABG, or a bare-metal stent (BMS) within 1 month before CABG.
- Patients with thrombocytopenia (<100 x 10⁹/L) before CABG.
- Patients with severe renal dysfunction requiring dialysis or active liver disease, including unexplained persistent transaminase elevation or transaminase levels >3× the upper normal limit.
- Patients using strong CYP3A4 inhibitors.
- Patients requiring methotrexate and ibuprofen therapy.
- Patients with active malignant tumors with an increased risk of bleeding, as determined by the investigator.
- Pregnant or breastfeeding women, and those who have given birth within the past 90 days.
- Premenopausal women not using adequate contraception. Adequate contraception requires at least two reliable methods, including one barrier method.
Quoted from ClinicalTrials.gov, NCT06981390, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06981390, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.